New Delhi [India], November 11 (ANI): Indian Medicines Pharmaceutical Corporation (IMPCL), a central public sector enterprise (CPSE), has announced to pay a dividend of Rs 10.13 crore to its stakeholders.

The dividend cheque of Rs 9.93 crore for the Ministry of Ayush was handed over to Union minister of Ayush Sarbananda Sonowal in a ceremony held at Transport Bhawan, on Thursday.

Also Read | NOW – Pentagon Spox Says “Twitter is a Massive Platform with Huge Reach” and That She … – Latest Tweet by Disclose.tv.

On this occasion, Sarbananda Sonowal said, "IMPCL has registered an impressive increase in its profits in comparison to the last Financial Year 2020-21, which is a commendable achievement. Under the visionary leadership of Prime Minister Narendra Modi, Ayush sector is witnessing all round growth not only in India but globally."

Mukesh Kumar, MD, IMPCL, said, "In the operational front the company has achieved an enhancement of 47% in capacity utilisation over its previous year. An all-around enhancement in performance in terms of turnover, profit and capacity utilisation over previous years has brought focus on the future prospects of the company."

Also Read | Astra, US-Based Rocket Startup, Lays Off 16 Percent of Its Workforce To Expand Its Core Business.

IMPCL has been conferred mini ratna Category II status by the government of India and also got ISO 9001:2015 Certification. The company is presently manufacturing 656 classical avurvedic, 332 unani and 71 proprietary ayurvedic medicines for the various diseases spectrum. It supplies ayurveda and unani medicines to all the states under National Ayush Mission (NAM) and 6,000 centres of Jan Aushadhi Kendras. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)